Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Delamanid Access Widened But TB Groups Want More

This article was originally published in PharmAsia News

Executive Summary

Otsuka has agreed a plan with the Global Drug Facility to improve the worldwide distribution of its novel TB drug delamanid, but several access groups are asking for additional action to combat the multidrug-resistant form of the disease.

Advertisement

Related Content

Indian Teen’s Fight For Lifesaving TB Drug Highlights Access Issues

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC089324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel